During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

Abstract The International Society for Influenza and other Respiratory Virus Diseases held its
6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13–15, 2018 …

Introducing novel strategies, concepts, and technologies that speed up drug discovery and
the drug development cycle is of great importance both in the highly competitive …

Ribonucleases (RNases) cleave and process RNAs, thereby regulating the biogenesis,
metabolism, and degradation of coding and noncoding RNAs. Thus, small molecules …

Baloxavir marboxil is a new drug developed in Japan by Shionogi to treat seasonal flu
infection. This cap-dependent endonuclease inhibitor is a prodrug that releases the …

The influenza virus RNA-dependent RNA polymerase (RdRP) cleaves the 5′ end of
nascent capped host RNAs and uses the capped RNA fragment to prime viral transcription …

Abstract Four 2, 4-disubstituted quinazoline series containing various amide moieties were
designed and synthesized as new anti-influenza A virus agents using the strategies of bio …

Evidence suggests that rapidly evolving virus subvariants risk rendering current vaccines
and anti-influenza drugs ineffective. Hence, exploring novel scaffolds or new targets of anti …

Influenza PAN inhibitors are of particular importance in current efforts to develop a new
generation of antiviral drugs due to the growing emergence of highly pathogenic influenza …

We report herein the synthesis of a series of novel quinoline derivatives, based on the lead
compound 1a, identified from a rRSV-mGFP high-throughput screening assay. Our results …